Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 147

1.

The status of epidermal growth factor receptor in borderline ovarian tumours.

Showeil R, Romano C, Valganon M, Lambros M, Trivedi P, Van Noorden S, Sriraksa R, El-Kaffash D, El-Etreby N, Natrajan R, Foroni L, Osborne R, El-Bahrawy M.

Oncotarget. 2016 Mar 1;7(9):10568-77. doi: 10.18632/oncotarget.7257.

2.

KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.

Tsang YT, Deavers MT, Sun CC, Kwan SY, Kuo E, Malpica A, Mok SC, Gershenson DM, Wong KK.

J Pathol. 2013 Dec;231(4):449-56. doi: 10.1002/path.4252.

3.

Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants.

Ardighieri L, Zeppernick F, Hannibal CG, Vang R, Cope L, Junge J, Kjaer SK, Kurman RJ, Shih IeM.

J Pathol. 2014 Jan;232(1):16-22. doi: 10.1002/path.4293.

4.

Molecular characterization of 103 ovarian serous and mucinous tumors.

Vereczkey I, Serester O, Dobos J, Gallai M, Szakács O, Szentirmay Z, Tóth E.

Pathol Oncol Res. 2011 Sep;17(3):551-9. doi: 10.1007/s12253-010-9345-8. Epub 2010 Dec 7.

PMID:
21136228
5.

KRAS, BRAF genotyping reveals genetic heterogeneity of ovarian borderline tumors and associated implants.

Heublein S, Grasse K, Hessel H, Burges A, Lenhard M, Engel J, Kirchner T, Jeschke U, Mayr D.

BMC Cancer. 2013 Oct 18;13:483. doi: 10.1186/1471-2407-13-483.

6.

BRAF mutation is associated with a specific cell type with features suggestive of senescence in ovarian serous borderline (atypical proliferative) tumors.

Zeppernick F, Ardighieri L, Hannibal CG, Vang R, Junge J, Kjaer SK, Zhang R, Kurman RJ, Shih IeM.

Am J Surg Pathol. 2014 Dec;38(12):1603-11. doi: 10.1097/PAS.0000000000000313. Erratum in: Am J Surg Pathol. 2015 Jul;39(7):1014.

7.

Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes.

Hunter SM, Anglesio MS, Ryland GL, Sharma R, Chiew YE, Rowley SM, Doyle MA, Li J, Gilks CB, Moss P, Allan PE, Stephens AN, Huntsman DG, deFazio A, Bowtell DD; Australian Ovarian Cancer Study Group, Gorringe KL, Campbell IG.

Oncotarget. 2015 Nov 10;6(35):37663-77. doi: 10.18632/oncotarget.5438.

8.

In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours.

Sieben NL, Macropoulos P, Roemen GM, Kolkman-Uljee SM, Jan Fleuren G, Houmadi R, Diss T, Warren B, Al Adnani M, De Goeij AP, Krausz T, Flanagan AM.

J Pathol. 2004 Mar;202(3):336-40.

PMID:
14991899
9.

Biomolecular pathogenesis of borderline ovarian tumors: focusing target discovery through proteogenomics.

Vergara D, Tinelli A, Martignago R, Malvasi A, Chiuri VE, Leo G.

Curr Cancer Drug Targets. 2010 Feb;10(1):107-16. Review.

PMID:
20088785
10.

Low-grade serous carcinomas of the ovary contain very few point mutations.

Jones S, Wang TL, Kurman RJ, Nakayama K, Velculescu VE, Vogelstein B, Kinzler KW, Papadopoulos N, Shih IeM.

J Pathol. 2012 Feb;226(3):413-20. doi: 10.1002/path.3967. Epub 2011 Dec 20.

11.

The molecular pathology of ovarian serous borderline tumors.

Malpica A, Wong KK.

Ann Oncol. 2016 Apr;27 Suppl 1:i16-i19. doi: 10.1093/annonc/mdw089.

12.

Expression of BRAF V600E mutant protein in epithelial ovarian tumors.

Preusser M, Capper D, Berghoff AS, Horvat R, Wrba F, Schindl M, Schoppmann SF, von Deimling A, Birner P.

Appl Immunohistochem Mol Morphol. 2013 Mar;21(2):159-64. doi: 10.1097/PAI.0b013e31825d7402.

PMID:
22820660
13.

Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.

Della Pepa C, Tonini G, Santini D, Losito S, Pisano C, Di Napoli M, Cecere SC, Gargiulo P, Pignata S.

Cancer Treat Rev. 2015 Feb;41(2):136-43. doi: 10.1016/j.ctrv.2014.12.003. Epub 2014 Dec 23. Review.

PMID:
25573350
14.

TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.

Rechsteiner M, Zimmermann AK, Wild PJ, Caduff R, von Teichman A, Fink D, Moch H, Noske A.

Exp Mol Pathol. 2013 Oct;95(2):235-41. doi: 10.1016/j.yexmp.2013.08.004. Epub 2013 Aug 18.

PMID:
23965232
15.

Association of epidermal growth factor receptor and mitogen-activated protein kinase with cystic neoplasms of the pancreas.

Kuboki Y, Shiratori K, Hatori T, Fujita I, Kimijima A, Yamamoto M, Kobayashi M, Furukawa T.

Mod Pathol. 2010 Aug;23(8):1127-35. doi: 10.1038/modpathol.2010.97. Epub 2010 May 21.

16.

Determination of BRAF V600E (VE1) protein expression and BRAF gene mutation status in codon 600 in borderline and low-grade ovarian cancers.

Sadlecki P, Walentowicz P, Bodnar M, Marszalek A, Grabiec M, Walentowicz-Sadlecka M.

Tumour Biol. 2017 May;39(5):1010428317706230. doi: 10.1177/1010428317706230.

PMID:
28488545
17.

Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR.

Bösmüller H, Fischer A, Pham DL, Fehm T, Capper D, von Deimling A, Bonzheim I, Staebler A, Fend F.

Hum Pathol. 2013 Mar;44(3):329-35. doi: 10.1016/j.humpath.2012.07.010. Epub 2012 Oct 22.

PMID:
23089489
18.

Epidermal growth factor receptor expression and KRAS and BRAF mutations: study of 39 sinonasal intestinal-type adenocarcinomas.

Projetti F, Durand K, Chaunavel A, Léobon S, Lacorre S, Caire F, Bessède JP, Moreau JJ, Coulibaly B, Labrousse F.

Hum Pathol. 2013 Oct;44(10):2116-25. doi: 10.1016/j.humpath.2013.03.019. Epub 2013 Jun 20.

PMID:
23791006
19.

BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas.

Wong KK, Tsang YT, Deavers MT, Mok SC, Zu Z, Sun C, Malpica A, Wolf JK, Lu KH, Gershenson DM.

Am J Pathol. 2010 Oct;177(4):1611-7. doi: 10.2353/ajpath.2010.100212. Epub 2010 Aug 27.

20.

Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.

Emmanuel C, Chiew YE, George J, Etemadmoghadam D, Anglesio MS, Sharma R, Russell P, Kennedy C, Fereday S, Hung J, Galletta L, Hogg R, Wain GV, Brand A, Balleine R, MacConaill L, Palescandolo E, Hunter SM, Campbell I, Dobrovic A, Wong SQ, Do H, Clarke CL, Harnett PR, Bowtell DD, deFazio A; Australian Ovarian Cancer Study (AOCS).

Clin Cancer Res. 2014 Dec 15;20(24):6618-30. doi: 10.1158/1078-0432.CCR-14-1292. Epub 2014 Oct 14. Erratum in: Clin Cancer Res. 2016 Aug 15;22(16):4272.

Supplemental Content

Support Center